• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

冠心病住院后高胆固醇血症治疗效果的相关因素。

Factors related to the effectiveness of hypercholesterolemia treatment following hospitalization for coronary artery disease.

作者信息

Jankowski Piotr, Czarnecka Danuta, Łukaszewska Anna, Łysek Radosław, Wolfshaut-Wolak Renata, Bogacki Piotr, Grodecki Janusz, Mirek-Bryniarska Ewa, Nessler Jadwiga, Podolec Piotr, Kawecka-Jaszcz Kalina, Pająk Andrzej

出版信息

Pol Arch Med Wewn. 2016 Jun 23;126(6):388-94. doi: 10.20452/pamw.3447.

DOI:10.20452/pamw.3447
PMID:27362391
Abstract

INTRODUCTION    Patients with established coronary artery disease (CAD) are at high risk of recurrent cardiovascular events. OBJECTIVES    The aim of the study was to identify factors related to control of hypercholesterolemia in patients after hospitalization for CAD. PATIENTS AND METHODS    The study included consecutive patients from 5 hospitals with cardiology departments serving one city in southern Poland. Patients were hospitalized for an acute coronary syndrome or for a myocardial revascularization procedure. Interviews and examinations were conducted 6 to 18 months after hospitalization. RESULTS    Overall, 83.6% of the patients were taking statins; 2.1%, fibrates; and 0.5%, ezetimibe. A statin at a high dose (≥40 mg of atorvastatin or ≥20 mg of rosuvastatin) was taken by 36.1% of the participants. Younger age and index hospitalization in a teaching hospital were significantly associated with a higher probability of taking a statin. Overall, 28.1% of the patients had good control of hypercholesterolemia (low-density lipoprotein [LDL] cholesterol levels <1.8 mmol/l), whereas 71.9%, 38.6%, 24.4%, and 10.3% had LDL cholesterol levels of 1.8 mmol/l or higher, 2.5 mmol/l or higher, 3.0 mmol/l or higher, and 4.0 mmol/l or higher, respectively. Younger age, high blood pressure, and high fasting glucose levels were related to a higher probability of having LDL cholesterol levels of 1.8 mmol/l or higher, while younger age, shorter period of education, professional inactivity, lack of cardiac rehabilitation, and high blood pressure were related to the probability of LDL cholesterol levels of 4.0 mmol/l or higher. CONCLUSIONS    The frequency of statin use is affected by age and health care-related factors, while control of hypercholesterolemia after hospitalization due to CAD is dependent mainly on patient-related and clinical factors.

摘要

引言

已确诊冠心病(CAD)的患者发生心血管事件复发的风险很高。

目的

本研究旨在确定冠心病住院患者高胆固醇血症控制的相关因素。

患者与方法

该研究纳入了波兰南部一个城市的5家设有心脏病科的医院的连续患者。患者因急性冠状动脉综合征或心肌血运重建术住院。在住院6至18个月后进行访谈和检查。

结果

总体而言,83.6%的患者服用他汀类药物;2.1%服用贝特类药物;0.5%服用依折麦布。36.1%的参与者服用高剂量他汀类药物(≥40毫克阿托伐他汀或≥20毫克瑞舒伐他汀)。年龄较小以及在教学医院进行首次住院治疗与服用他汀类药物的可能性较高显著相关。总体而言,28.1%的患者高胆固醇血症得到良好控制(低密度脂蛋白[LDL]胆固醇水平<1.8毫摩尔/升),而71.9%、38.6%、24.4%和10.3%的患者LDL胆固醇水平分别为1.8毫摩尔/升或更高、2.5毫摩尔/升或更高、3.0毫摩尔/升或更高以及4.0毫摩尔/升或更高。年龄较小、高血压和空腹血糖水平较高与LDL胆固醇水平为1.8毫摩尔/升或更高的可能性较高相关,而年龄较小、教育年限较短、职业不活动、缺乏心脏康复以及高血压与LDL胆固醇水平为4.0毫摩尔/升或更高的可能性相关。

结论

他汀类药物的使用频率受年龄和医疗保健相关因素影响,而冠心病住院后高胆固醇血症的控制主要取决于患者相关因素和临床因素。

相似文献

1
Factors related to the effectiveness of hypercholesterolemia treatment following hospitalization for coronary artery disease.冠心病住院后高胆固醇血症治疗效果的相关因素。
Pol Arch Med Wewn. 2016 Jun 23;126(6):388-94. doi: 10.20452/pamw.3447.
2
Secondary prevention of coronary artery disease in contemporary clinical practice.当代临床实践中冠状动脉疾病的二级预防
Cardiol J. 2015;22(2):219-26. doi: 10.5603/CJ.a2014.0066. Epub 2014 Oct 9.
3
Incremental cholesterol reduction with ezetimibe/simvastatin, atorvastatin and rosuvastatin in UK General Practice (IN-PRACTICE): randomised controlled trial of achievement of Joint British Societies (JBS-2) cholesterol targets.依泽替米贝/辛伐他汀、阿托伐他汀和瑞舒伐他汀在英国普通实践中的胆固醇逐步降低(IN-PRACTICE):联合英国学会(JBS-2)胆固醇目标的实现的随机对照试验。
Int J Clin Pract. 2010 Jul;64(8):1052-61. doi: 10.1111/j.1742-1241.2010.02429.x. Epub 2010 May 12.
4
Lipid-altering efficacy of ezetimibe/simvastatin 10/40 mg compared with doubling the statin dose in patients admitted to the hospital for a recent coronary event: the INFORCE study.依折麦布/辛伐他汀10/40毫克与将他汀类药物剂量加倍相比,对近期因冠心病事件入院患者的血脂改变疗效:INFORCE研究
Int J Clin Pract. 2008 Apr;62(4):539-54. doi: 10.1111/j.1742-1241.2008.01697.x. Epub 2008 Feb 11.
5
Comparative effects of 10-mg versus 80-mg Atorvastatin on high-sensitivity C-reactive protein in patients with stable coronary artery disease: results of the CAP (Comparative Atorvastatin Pleiotropic effects) study.10毫克与80毫克阿托伐他汀对稳定型冠状动脉疾病患者高敏C反应蛋白的比较效应:CAP(阿托伐他汀多效性比较)研究结果
Clin Ther. 2008 Dec;30(12):2298-313. doi: 10.1016/j.clinthera.2008.12.023.
6
Twelve-week, multicenter, randomized, open-label comparison of the effects of rosuvastatin 10 mg/d and atorvastatin 10 mg/d in high-risk adults: a DISCOVERY study.瑞舒伐他汀10毫克/天与阿托伐他汀10毫克/天对高危成年人影响的12周多中心随机开放标签比较:一项探索性研究
Clin Ther. 2004 Nov;26(11):1821-33. doi: 10.1016/j.clinthera.2004.11.015.
7
Comparison of rosuvastatin with atorvastatin, simvastatin and pravastatin in achieving cholesterol goals and improving plasma lipids in hypercholesterolaemic patients with or without the metabolic syndrome in the MERCURY I trial.在MERCURY I试验中,瑞舒伐他汀与阿托伐他汀、辛伐他汀和普伐他汀在实现胆固醇目标及改善伴有或不伴有代谢综合征的高胆固醇血症患者血脂方面的比较。
Diabetes Obes Metab. 2005 Jul;7(4):430-8. doi: 10.1111/j.1463-1326.2004.00450.x.
8
Reduction in estimated risk for coronary artery disease after use of ezetimibe with a statin.使用依折麦布与他汀类药物联合治疗后,冠状动脉疾病估计风险降低。
Ann Pharmacother. 2007 Sep;41(9):1345-51. doi: 10.1345/aph.1K140. Epub 2007 Jul 31.
9
Comparison of the efficacy of rosuvastatin versus atorvastatin, simvastatin, and pravastatin in achieving lipid goals: results from the STELLAR trial.瑞舒伐他汀与阿托伐他汀、辛伐他汀及普伐他汀在实现血脂目标方面的疗效比较:STELLAR试验结果
Curr Med Res Opin. 2003;19(8):689-98. doi: 10.1185/030079903125002405.
10
Treatment with ezetimibe plus low-dose atorvastatin compared with higher-dose atorvastatin alone: is sufficient cholesterol-lowering enough to inhibit platelets?依折麦布联合低剂量阿托伐他汀治疗与单独使用高剂量阿托伐他汀治疗相比:足够的胆固醇降低幅度是否足以抑制血小板?
J Am Coll Cardiol. 2007 Mar 13;49(10):1035-42. doi: 10.1016/j.jacc.2006.10.064. Epub 2007 Feb 23.

引用本文的文献

1
PoLA/CFPiP/PCS/PSLD/PSD/PSH guidelines on diagnosis and therapy of lipid disorders in Poland 2021.2021年波兰脂质紊乱诊断与治疗的PoLA/CFPiP/PCS/PSLD/PSD/PSH指南
Arch Med Sci. 2021 Nov 8;17(6):1447-1547. doi: 10.5114/aoms/141941. eCollection 2021.
2
Dyslipidemia Management in Patients with Coronary Artery Disease. Data from the POLASPIRE Survey.冠状动脉疾病患者的血脂异常管理。来自POLASPIRE调查的数据。
J Clin Med. 2021 Aug 20;10(16):3711. doi: 10.3390/jcm10163711.
3
Role of Lipid-Lowering Therapy in Low-Density Lipoprotein Cholesterol Goal Attainment: Focus on Patients With Acute Coronary Syndrome.
降脂治疗在 LDL-C 达标中的作用:关注急性冠脉综合征患者。
J Cardiovasc Pharmacol. 2020 Dec;76(6):658-670. doi: 10.1097/FJC.0000000000000914.
4
PoLA/CFPiP/PCS Guidelines for the Management of Dyslipidaemias for Family Physicians 2016.2016年家庭医生血脂异常管理的PoLA/CFPiP/PCS指南
Arch Med Sci. 2017 Feb 1;13(1):1-45. doi: 10.5114/aoms.2017.64712. Epub 2016 Dec 19.